Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yubo International Biotech Limited (YBGJ)
USD0.01
+0.01 (+109.86%)
CN OTC Healthcare Medical - Instruments & Supplies
Address
Building 5
Beijing, CN
Beijing, CN
CEO
Yang Wang
Website
yubogroup.com
IPO
2021-08-24
CIK 895464 ISIN US9883661004
Description
Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells. Beyond this core focus, the company also provides a diverse range of products, including solutions for respiratory health, skincare and hair care formulations, nutritious beverages, and personal care items tailored for both men and women. Furthermore, it delivers specialized stem cell services, such as cellular analysis and comprehensive health management consulting, all offered under the VIVCELL brand. The company's headquarters are located in Beijing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.01 (+109.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.6K
Beta
0.63
Float Shares
10.54M
Free Float %
8.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -16.00% | -26.96% | -42.35% | -32.26% | -81.74% | -90.33% | -98.13% | -98.13% | -98.13% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-24.95
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+3,772.9% ★
-
EPS growth Medical - Instruments & Supplies: +16.3%+48.0% ★ Q1'26: +55.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-545.9%
-
EBIT margin Medical - Instruments & Supplies: +13.5%-883.8%
-
ROIC Medical - Instruments & Supplies: +6.0%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+16.5% Q1'26: +42.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-0.08× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-573.5K
OE per share TTM
0.00
Owner's Yield
-40.06%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
209.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Magna Acquisition LLC (FEIN No. 20-3144686) | 60.77M | 55.80% | 60.77M | — | 60.77M | 10.00 | OO | Delaware | 2005-11-08 | ↗ |
| 2 | Flydragon International Limited | 39.94M | 33.80% | 39.94M | — | 39.94M | — | OO | British Virgin Islands | 2021-01-21 | ↗ |
| 3 | Jun Wang | 39.94M | 33.80% | 39.94M | — | 39.94M | — | IN | China | 2021-01-21 | ↗ |
| 4 | Boao Biotech Limited | 24.97M | 21.10% | 24.97M | — | 24.97M | — | OO | British Virgin Islands | 2021-01-21 | ↗ |
| 5 | Chinaone Technology Limited | 19.21M | 16.30% | 19.21M | — | 19.21M | — | OO | British Virgin Islands | 2021-01-25 | ↗ |
| 6 | Yang Wang | 19.21M | 16.30% | 19.21M | — | 19.21M | — | IN | China | 2021-01-25 | ↗ |
| 7 | Focusone Technology Group Limited | 11.52M | 9.80% | 11.52M | — | 11.52M | — | OO | — | 2021-01-21 | ↗ |
| 8 | Focus Draw Group Limited | 9.10M | 7.60% | — | 9.10M | — | 9.10M | OO | British Virgin Islands | 2022-11-10 | ↗ |
| 9 | Lina Liu | 9.10M | 7.60% | — | 9.10M | — | 9.10M | IN | China | 2022-11-10 | ↗ |
| 10 | Cheung Ho Shun | 7.12M | 5.90% | 7.12M | — | 7.12M | — | IN | Hong Kong | 2022-11-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
50.60M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+50,600,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-23 | Wang Yang | Director / Officer / 10% Owner | A-Award | A | Class A Common Stock | 8,600,000 | 0.05 | 430.0K | 25,811,400 | I | ↗ |
| 2025-07-23 | Wang Jun | Director / Officer / 10% Owner | A-Award | A | Class A Common Stock | 42,000,000 | 0.05 | 2.10M | 81,943,800 | I | ↗ |
| 2025-05-05 | HU NANPING | Director | — | — | Class A Common Stock, par value $0.001 per share | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-07-15 | Wang Yang | Director / Officer / 10% Owner | S-Sale | D | Class A Common Stock | 2,000,000 | 0.12 | 240.0K | 17,211,400 | I | ↗ |
| 2024-01-25 | Boao Biotech Ltd | 10% Owner | S-Sale | D | Class A Common Stock | 86,897 | 0.30 | 26.1K | 22,792,074 | D | ↗ |
| 2022-11-09 | Liu Lina | Director / Officer | S-Sale | D | Class A Common Stock | 4,728,000 | 0.50 | 2.36M | 9,101,400 | — | ↗ |
| 2022-09-23 | Focus Draw Group Ltd | — | S-Sale | D | Class A Common Stock | 4,728,000 | 0.50 | 2.36M | 9,101,400 | — | ↗ |
| 2021-01-14 | Yang Wang | Director / 10% Owner | P-Purchase | A | Class A Common Stock | 19,211,400 | 0.00 | — | 19,211,400 | — | ↗ |
| 2021-01-14 | Liu Lina | Officer | P-Purchase | A | Class A Common Stock | 13,829,400 | 0.00 | — | 13,829,400 | — | ↗ |
| 2021-01-14 | Jun Wang | Director / Officer / 10% Owner | P-Purchase | A | Class A Common Stock | 39,943,800 | 0.00 | — | 39,943,800 | — | ↗ |
| 2021-01-14 | Focus Draw Group Ltd | 10% Owner | — | D | Class A Common Stock | 0 | 0.00 | — | 13,829,400 | — | ↗ |
| 2021-01-14 | Flydragon International Ltd | 10% Owner | — | D | Class A Common Stock | 0 | 0.00 | — | 39,943,800 | — | ↗ |
| 2021-01-14 | Chinaone Technology Ltd | 10% Owner | — | D | Class A Common Stock | 0 | 0.00 | — | 19,211,400 | — | ↗ |
| 2021-01-14 | Boao Biotech Ltd | 10% Owner | — | D | Class A Common Stock | 0 | 0.00 | — | 24,967,800 | — | ↗ |
| 2020-10-12 | Zhihui Bai | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-12 | Yang Wang | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-12 | Jun Wang | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-02 | Liu Lina | Officer / 10% Owner | — | D | Series A Common Stock | 0 | 0.00 | — | 116,697,438 | — | ↗ |
| 2005-10-31 | Riscica Kenneth C | Officer | A-Award | A | Class A Common Stock | 610,212 | 23,400.00 | 14.28B | 610,212 | — | ↗ |
| 2005-10-31 | Minkoff Lawrence A | Director / Officer | A-Award | A | Class A Common Stock | 764,068 | 29,300.00 | 22.39B | 764,068 | — | ↗ |
| 2005-10-31 | Magna Acquisition LLC | 10% Owner | — | D | Class A Common Stock, $0.001 par value | 0 | 0.00 | — | 60,772,729 | — | ↗ |
| 2005-10-31 | Kessler Seymour | Director | A-Award | A | Class A Common Stock | 142,035 | 5,417.00 | 769.40M | 142,035 | — | ↗ |
| 2005-10-31 | KANTER JOEL S | Director | D-Return | D | Stock Options | 75,000 | 0.25 | 18.8K | 0 | — | ↗ |
| 2005-10-31 | Feldman Jerome M | Director | D-Return | D | Stock Options | 1,575,000 | 0.28 | 441.0K | 0 | — | ↗ |
| 2005-10-31 | ADERETH JONATHAN | Director | A-Award | A | Class A common stock | 208,620 | 8,000.00 | 1.67B | 208,620 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-660.00
Shares Outstanding
119.82M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Wang | President & Director | 68.3K | male |
| Lina Liu | Chief Financial Officer, Treasurer, Secretary & Director | 51.2K | female |
| Yang Wang | Chief Executive Officer & Director | 51.2K | male |
| Jin Wei | Co-Owner | — | male |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YBGJ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
